Metabolic control of RNA methylation in rheumatoid arthritis: from synovial stress to pathogenic cellular adaptation - Report - MDSpire

Regulation of RNA Methylation by Metabolism in Rheumatoid Arthritis: Linking Synovial Stress to Pathogenic Cellular Changes

  • By

  • Shu Li

  • Lei Wan

  • Jin Yang

  • Kun Wang

  • Xiaojun Zhang

  • Xiaochuang Liu

  • July 17, 2026

Share

Regulation of RNA Methylation by Metabolism in Rheumatoid Arthritis

Background

Rheumatoid arthritis is a chronic autoimmune disorder that leads to significant joint damage and disability. Understanding the mechanisms that drive persistent inflammation and tissue destruction is crucial. Recent research has identified metabolic reprogramming and RNA methylation as key factors in the pathogenesis of RA.

Data Highlights

No numerical data or trial data presented in the article.

Key Findings

  • RNA methylation, particularly m6A, plays a critical role in regulating immune and stromal cell adaptation in RA.
  • Metabolic stress conditions, such as hypoxia and oxidative stress, influence RNA methylation patterns in synovial cells.
  • In fibroblast-like synoviocytes, RNA methylation supports glycolytic fitness and resistance to apoptosis.
  • Macrophages exhibit enhanced inflammatory polarization due to RNA methylation changes.
  • RNA methylation contributes to Th17 skewing and excessive neutrophil extracellular trap formation in T cells and neutrophils.

Clinical Implications

Understanding the pathways involved in metabolic stress and RNA methylation is important for future research in RA.

Conclusion

The integration of metabolic and epitranscriptomic changes in RA highlights the complexity of its pathogenesis.

Related Resources & Content

  1. Frontiers in Immunology, 2026 -- Epitranscriptomic regulation by m6A in immunity and autoimmune disorders: emerging mechanisms and clinical perspectives
  2. Clinical Rheumatology, 2015 -- Evaluating the Immunological Rationale for Using Methotrexate in Conjunction with TNF Inhibitors and Tocilizumab
  3. Frontiers in Immunology, 2026 -- Systemic regulation of rheumatoid arthritis by mesenchymal stem cells: from immune homeostasis to microbiota modulation
  4. Frontiers in Immunology, 2026 -- The SIRT1/STAT3 axis as a central regulator of immune, inflammatory, and lipid metabolic dysregulation in rheumatoid arthritis: therapeutic implications
  5. EULAR, 2026 -- Current guideline landscape
  6. FDA -- FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions
  7. ScienceDirect -- Glycolysis, a driving force of rheumatoid arthritis
  8. https://www.eular.org/document/download/1406/ec021a77-cdf3-4de3-ae72-57c1757db549/1325
  9. FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions | FDA
  10. Glycolysis, a driving force of rheumatoid arthritis - ScienceDirect

Original Source(s)

Related Content